Trimetrexate
| Title | Journal |
|---|---|
| KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells. | Molecular cancer therapeutics 20140601 |
| CoMFA/CoMSIA 3D-QSAR of pyrimidine inhibitors of Pneumocystis carinii dihydrofolate reductase. | Journal of molecular modeling 20120901 |
| Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy. | Human gene therapy 20120701 |
| Exploiting ligand-protein conjugates to monitor ligand-receptor interactions. | PloS one 20120101 |
| Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). | PLoS computational biology 20111201 |
| [Diagnosis and treatment of pneumocystis jirovecii pneumonia]. | Deutsche medizinische Wochenschrift (1946) 20110701 |
| Consensus-phenotype integration of transcriptomic and metabolomic data implies a role for metabolism in the chemosensitivity of tumour cells. | PLoS computational biology 20110301 |
| Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants. | Cancer chemotherapy and pharmacology 20110201 |
| Impairment of methotrexate transport is common in osteosarcoma tumor samples. | Sarcoma 20110101 |
| A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers. | Malaria journal 20110101 |
| Chemotherapy in advanced bladder cancer: current status and future. | Journal of hematology & oncology 20110101 |
| High-resolution structures of Trypanosoma brucei pteridine reductase ligand complexes inform on the placement of new molecular entities in the active site of a potential drug target. | Acta crystallographica. Section D, Biological crystallography 20101201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20101201 |
| The immunobiology of cord blood transplantation. | The Korean journal of hematology 20101201 |
| Radiation recall with anticancer agents. | The oncologist 20101101 |
| Synthesis and biological evaluation of biguanide and dihydrotriazine derivatives as potential inhibitors of dihydrofolate reductase of opportunistic microorganisms. | Journal of enzyme inhibition and medicinal chemistry 20100601 |
| Synthesis and characterization of potent inhibitors of Trypanosoma cruzi dihydrofolate reductase. | Bioorganic & medicinal chemistry 20100601 |
| S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach. | American journal of clinical oncology 20100401 |
| Anticancer agents against malaria: time to revisit? | Trends in parasitology 20100301 |
| 2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors. | Bioorganic & medicinal chemistry 20100115 |
| Comparison of methods for evaluating drug-drug interaction. | Frontiers in bioscience (Elite edition) 20100101 |
| Comparison of methods for statistical analysis of combination studies. | Frontiers in bioscience (Elite edition) 20100101 |
| Efficient experimental design and nonparametric modeling of drug interaction. | Frontiers in bioscience (Elite edition) 20100101 |
| Application and review of the separate ray model to investigate interaction effects. | Frontiers in bioscience (Elite edition) 20100101 |
| Applying Emax model and bivariate thin plate splines to assess drug interactions. | Frontiers in bioscience (Elite edition) 20100101 |
| Emax model and interaction index for assessing drug interaction in combination studies. | Frontiers in bioscience (Elite edition) 20100101 |
| A review of synergy concepts of nonlinear blending and dose-reduction profiles. | Frontiers in bioscience (Scholar edition) 20100101 |
| Academia-pharma intersect: providing a broader perspective on drug development synergies between academia and industry. | The oncologist 20100101 |
| Cancer chemotherapy: targeting folic acid synthesis. | Cancer management and research 20100101 |
| Management of Pneumocystis Jirovecii pneumonia in HIV infected patients: current options, challenges and future directions. | HIV/AIDS (Auckland, N.Z.) 20100101 |
| Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. | The Journal of antimicrobial chemotherapy 20091201 |
| A mapping of drug space from the viewpoint of small molecule metabolism. | PLoS computational biology 20090801 |
| Structures of dihydrofolate reductase-thymidylate synthase of Trypanosoma cruzi in the folate-free state and in complex with two antifolate drugs, trimetrexate and methotrexate. | Acta crystallographica. Section D, Biological crystallography 20090701 |
| Trimetrexate and folinic acid: a valuable salvage option for Pneumocystis jirovecii pneumonia. | AIDS (London, England) 20090619 |
| Interpretable correlation descriptors for quantitative structure-activity relationships. | Journal of cheminformatics 20090101 |
| Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. | Journal of medicinal chemistry 20081113 |
| N9-substituted 2,4-diaminoquinazolines: synthesis and biological evaluation of lipophilic inhibitors of pneumocystis carinii and toxoplasma gondii dihydrofolate reductase. | Journal of medicinal chemistry 20081009 |
| Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy. | Reviews on recent clinical trials 20080901 |
| Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity. | Journal of medicinal chemistry 20080828 |
| The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents. | Journal of medicinal chemistry 20080814 |
| Chemical and genetic validation of dihydrofolate reductase-thymidylate synthase as a drug target in African trypanosomes. | Molecular microbiology 20080701 |
| Effect of folate derivatives on the activity of antifolate drugs used against malaria and cancer. | Parasitology research 20080501 |
| Impairments in antifolate transport are common in retinoblastoma tumor samples. | Pediatric blood & cancer 20080301 |
| Radiation recall dermatitis: case report and review of the literature. | Current oncology (Toronto, Ont.) 20080101 |
| Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier. | BMC cancer 20080101 |
| Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy. | BMC gastroenterology 20080101 |
| Effects of folate and folylpolyglutamyl synthase modulation on chemosensitivity of breast cancer cells. | Molecular cancer therapeutics 20071101 |
| Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability. | The oncologist 20070701 |
| Design and synthesis of classical and nonclassical 6-arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as antifolates. | Journal of medicinal chemistry 20070628 |
| Dihydrofolate reductase as a target for chemotherapy in parasites. | Current pharmaceutical design 20070101 |
| Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies. | Anticancer research 20070101 |
| A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. | British journal of cancer 20061218 |
| Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. | Cancer chemotherapy and pharmacology 20061201 |
| Complete regression of large solid tumors using engineered drug-resistant hematopoietic cells and anti-CD137 immunotherapy. | Human gene therapy 20060801 |
| The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line. | Molecular cancer therapeutics 20060201 |
| Towards species-specific antifolates. | Current medicinal chemistry 20060101 |
| The protection against trimetrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-fluorouracil/trimetrexate. | Anticancer research 20060101 |
| A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer. | American journal of clinical oncology 20051001 |
| Tolerance by selective in vivo expansion of foreign major histocompatibility complex-transduced autologous bone marrow. | Transplantation 20050815 |
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | Chemical research in toxicology 20050601 |
| Highly efficient transduction of repopulating bone marrow cells using rapidly concentrated polymer-complexed retrovirus. | Biochemical and biophysical research communications 20050513 |
| Superior depletion of alloreactive T cells from peripheral blood stem cell and umbilical cord blood grafts by the combined use of trimetrexate and interleukin-2 immunotoxin. | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20041101 |
| Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance. | Emerging infectious diseases 20041001 |
| Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040915 |
| Structural studies on bioactive compounds. 39. Biological consequences of the structural modification of DHFR-inhibitory 2,4-diamino-6-(4-substituted benzylamino-3-nitrophenyl)-6-ethylpyrimidines ('benzoprims'). | Journal of medicinal chemistry 20040729 |
| Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors. | Journal of medicinal chemistry 20040701 |
| p14ARF expression increases dihydrofolate reductase degradation and paradoxically results in resistance to folate antagonists in cells with nonfunctional p53. | Cancer research 20040615 |
| Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase. | Journal of medicinal chemistry 20040506 |
| Design, synthesis, and computational affinity prediction of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20040501 |
| Preliminary in vitro studies on two potent, water-soluble trimethoprim analogues with exceptional species selectivity against dihydrofolate reductase from Pneumocystis carinii and Mycobacterium avium. | Bioorganic & medicinal chemistry letters 20040405 |
| Structure determination of tetrahydroquinazoline antifolates in complex with human and Pneumocystis carinii dihydrofolate reductase: correlations between enzyme selectivity and stereochemistry. | Acta crystallographica. Section D, Biological crystallography 20040401 |
| Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma. | American journal of clinical oncology 20040401 |
| 19F-magnetic resonance spectroscopy in patients with liver metastases of colorectal cancer treated with 5-fluorouracil. | Anti-cancer drugs 20040301 |
| Transient in vivo selection of transduced peripheral blood cells using antifolate drug selection in rhesus macaques that received transplants with hematopoietic stem cells expressing dihydrofolate reductase vectors. | Blood 20040201 |
| Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents. | Journal of medicinal chemistry 20031106 |
| A new nonlinear mixture response surface paradigm for the study of synergism: a three drug example. | Current drug metabolism 20031001 |
| Imaging of dihydrofolate reductase fusion gene expression in xenografts of human liver metastases of colorectal cancer in living rats. | European journal of nuclear medicine and molecular imaging 20030901 |
| Separation and determination of the antitumor drug piritrexim by molecularly imprinted microspheres in high-performance liquid chromatography. | Analytical and bioanalytical chemistry 20030901 |
| Thymidine and hypoxanthine protection patterns of the folic acid-enhanced synergies for combinations of trimetrexate plus a polyglutamylatable inhibitor of purine or thymidylate synthesis against human ileocecal HCT-8 cells. | International journal of oncology 20030801 |
| Increased resistance to nitrogen mustards and antifolates following in vitro selection of murine fibroblasts and primary hematopoietic cells transduced with a bicistronic retroviral vector expressing the rat glutathione S-transferase A3 and a mutant dihydrofolate reductase. | Cancer gene therapy 20030801 |
| Dihydrofolate reductase mutant with exceptional resistance to methotrexate but not to trimetrexate. | Journal of medicinal chemistry 20030703 |
| Sulfa resistance and dihydropteroate synthase mutants in recurrent Pneumocystis carinii pneumonia. | Emerging infectious diseases 20030701 |
| Analysis of two polymorphic forms of a pyrido[2,3-d]pyrimidine N9-C10 reversed-bridge antifolate binary complex with human dihydrofolate reductase. | Acta crystallographica. Section D, Biological crystallography 20030401 |
| Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line. | Biochemical pharmacology 20030401 |
| Trimetrexate inhibits progression of the murine 32Dp210 model of chronic myeloid leukemia in animals expressing drug-resistant dihydrofolate reductase. | Cancer research 20030315 |
| Novel antifolate drugs. | Current oncology reports 20030301 |
| The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis. | Biochemical pharmacology 20030301 |
| Large diversity in transport-mediated methotrexate resistance in human leukemia cell line CCRF-CEM established in a high concentration of leucovorin. | Cancer science 20030201 |
| Chemotherapy for malignant pleural mesothelioma: past results and recent developments. | British journal of cancer 20030127 |
| Quinoxaline chemistry. Part 15. 4-[2-Quinoxalylmethylenimino]-benzoylglutamates and -benzoates, 4-[2-quinoxalylmethyl-N-methylamino]-benzoylglutamates as analogues of classical antifolate agents. Synthesis, elucidation of structures and in vitro evaluation of antifolate and anticancer activities. | Farmaco (Societa chimica italiana : 1989) 20030101 |
| Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer. | International journal of gastrointestinal cancer 20030101 |
| Role of the E45K-reduced folate carrier gene mutation in methotrexate resistance in human leukemia cells. | Leukemia 20021201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20021201 |
| Synthesis of classical and nonclassical, partially restricted, linear, tricyclic 5-deaza antifolates. | Journal of medicinal chemistry 20021107 |
| Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines. | The Biochemical journal 20021101 |
| Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group study. | Investigational new drugs 20021101 |
| The murine-reduced folate carrier gene can act as a selectable marker and a suicide gene in hematopoietic cells in vivo. | Human gene therapy 20020920 |
| Analysis of quinazoline and pyrido[2,3-d]pyrimidine N9-C10 reversed-bridge antifolates in complex with NADP+ and Pneumocystis carinii dihydrofolate reductase. | Acta crystallographica. Section D, Biological crystallography 20020901 |
| Trimetrexate in relapsed T-cell lymphoma with skin involvement. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020615 |
| Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a gynecologic oncology group study. | Gynecologic oncology 20020501 |
| Low-dose trimetrexate glucuronate and protracted 5-fluorouracil infusion in previously untreated patients with advanced pancreatic cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20020401 |
| Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group. | Gynecologic oncology 20020101 |
| In vivo selection of antifolate-resistant transgenic hematopoietic stem cells in a murine bone marrow transplant model. | The Journal of pharmacology and experimental therapeutics 20020101 |
| Modulation of 5-fluorouracil/leucovorin by trimetrexate--did it work? | Annals of oncology : official journal of the European Society for Medical Oncology 20020101 |
| A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20020101 |
| Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study. | Annals of oncology : official journal of the European Society for Medical Oncology 20020101 |
| Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20020101 |
| Methylthioadenosine phosphorylase as target for chemoselective treatment of T-cell acute lymphoblastic leukemic cells. | Blood cells, molecules & diseases 20020101 |
| Severe folate restriction results in depletion of and alteration in the composition of the intracellular folate pool, moderate sensitization to methotrexate and trimetrexate, upregulation of endogenous DHFR activity, and overexpression of metallothionein II and folate receptor alpha that, upon folate repletion, confer drug resistance to CHL cells. | Journal of experimental therapeutics & oncology 20020101 |
| Synthesis of 2,4-diamino-6-(thioarylmethyl)pyrido[2,3-d]pyrimidines as dihydrofolate reductase inhibitors. | Bioorganic & medicinal chemistry 20011101 |
| Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20011001 |
| Pre-clinical evaluation of an in vitro selection protocol for the enrichment of transduced CD34+ cell-derived human dendritic cells. | Gene therapy 20010901 |
| Antifolate resistance and its circumvention by new analogues. | Human cell 20010901 |
| Structural studies on bioactive compounds. 34. Design, synthesis, and biological evaluation of triazenyl-substituted pyrimethamine inhibitors of Pneumocystis carinii dihydrofolate reductase. | Journal of medicinal chemistry 20010802 |
| Design, synthesis, computational prediction, and biological evaluation of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii. | Journal of medicinal chemistry 20010719 |
| A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. | Archives of internal medicine 20010625 |
| Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines. | Journal of medicinal chemistry 20010607 |
| RD114-pseudotyped oncoretroviral vectors. Biological and physical properties. | Annals of the New York Academy of Sciences 20010601 |
| New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. | The Lancet. Oncology 20010501 |
| Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. | Biochemical pharmacology 20010401 |
| Acute graft-vs-host disease: pathobiology and management. | Experimental hematology 20010301 |
| Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase. | Antimicrobial agents and chemotherapy 20001101 |
| Structure-based design of selective inhibitors of dihydrofolate reductase: synthesis and antiparasitic activity of 2, 4-diaminopteridine analogues with a bridged diarylamine side chain. | Journal of medicinal chemistry 19991118 |
| Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines. | Journal of medicinal chemistry 19990701 |
| 6-Substituted 2,4-diaminopyrido[3,2-d]pyrimidine analogues of piritrexim as inhibitors of dihydrofolate reductase from rat liver, Pneumocystis carinii, and Toxoplasma gondii and as antitumor agents. | Journal of medicinal chemistry 19981105 |
| Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents. | Journal of medicinal chemistry 19980827 |
| Synthesis and biological activities of tricyclic conformationally restricted tetrahydropyrido annulated furo[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases. | Journal of medicinal chemistry 19980423 |
| Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines. | Journal of medicinal chemistry 19980409 |
| 2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. | Journal of medicinal chemistry 19980312 |
| Folate and antifolate pharmacology. | Seminars in oncology 19971001 |
| Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii. | Journal of medicinal chemistry 19970912 |
| Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents. | Journal of medicinal chemistry 19970912 |
| Structural studies on bioactive compounds. 28. Selective activity of triazenyl-substituted pyrimethamine derivatives against Pneumocystis carinii dihydrofolate reductase. | Journal of medicinal chemistry 19970606 |
| Synthesis and biological activities of conformationally restricted, tricyclic nonclassical antifolates as inhibitors of dihydrofolate reductases. | Journal of medicinal chemistry 19970606 |
| Effect of N9-methylation and bridge atom variation on the activity of 5-substituted 2,4-diaminopyrrolo[2,3-d]pyrimidines against dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii. | Journal of medicinal chemistry 19970328 |
| Synthesis and dihydrofolate reductase inhibitory activities of 2,4-diamino-5-deaza and 2,4-diamino-5,10-dideaza lipophilic antifolates. | Journal of medicinal chemistry 19970214 |
| Synthesis and biological evaluation of nonclassical 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines with novel side chain substituents as potential inhibitors of dihydrofolate reductases. | Journal of medicinal chemistry 19970214 |
| Nonclassical 2,4-diamino-8-deazafolate analogues as inhibitors of dihydrofolate reductases from rat liver, Pneumocystis carinii, and Toxoplasma gondii. | Journal of medicinal chemistry 19960426 |
| 2,4-diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases. | Journal of medicinal chemistry 19960329 |
| Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations. | Journal of medicinal chemistry 19960315 |
| High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size. | Journal of medicinal chemistry 19960216 |
| New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii. | Journal of medicinal chemistry 19951124 |
| Evaluation of potent inhibitors of dihydrofolate reductase in a culture model for growth of Pneumocystis carinii. | Antimicrobial agents and chemotherapy 19951101 |
| Selective inhibitors of Candida albicans dihydrofolate reductase: activity and selectivity of 5-(arylthio)-2,4-diaminoquinazolines. | Journal of medicinal chemistry 19950901 |
| Nonclassical 2,4-diamino-6-(aminomethyl)-5,6,7,8-tetrahydroquinazoline antifolates: synthesis and biological activities. | Journal of medicinal chemistry 19950901 |
| 2,4-Diaminopyrido[3,2-d]pyrimidine inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii. | Journal of medicinal chemistry 19950707 |
| Novel 2,4-diamino-5-substituted-pyrrolo[2,3-d]pyrimidines as classical and nonclassical antifolate inhibitors of dihydrofolate reductases. | Journal of medicinal chemistry 19950609 |
| 6-substituted 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents. | Journal of medicinal chemistry 19950512 |
| 2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii. | Journal of medicinal chemistry 19950303 |
| 2,4-Diamino-5-chloroquinazoline analogues of trimetrexate and piritrexim: synthesis and antifolate activity. | Journal of medicinal chemistry 19941223 |
| FDA approved new drug bulletin: torsemide (Demadex), trimetrexate glucuronate (neuTrexin). | RN 19940501 |
| Trimetrexate in advanced hormone-refractory prostate cancer. An ECOG phase II trial. | Investigational new drugs 19940101 |
| Synthesis of 5-methyl-5-deaza nonclassical antifolates as inhibitors of dihydrofolate reductases and as potential antipneumocystis, antitoxoplasma, and antitumor agents. | Journal of medicinal chemistry 19931029 |
| 2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. | Journal of medicinal chemistry 19931015 |
| Identification of highly potent and selective inhibitors of Toxoplasma gondii dihydrofolate reductase. | Antimicrobial agents and chemotherapy 19930901 |
| Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. | Antimicrobial agents and chemotherapy 19920901 |
| Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs. | Antimicrobial agents and chemotherapy 19910701 |
| Inhibition of Pneumocystis dihydrofolate reductase by analogs of pyrimethamine, methotrexate and trimetrexate. | The Journal of protozoology 19910101 |
| Metabolic disposition of trimetrexate, a nonclassical dihydrofolate reductase inhibitor, in rat and dog. | Drug metabolism and disposition: the biological fate of chemicals 19900101 |
| Trimetrexate-leucovorin dosage evaluation study for treatment of Pneumocystis carinii pneumonia. | The Journal of infectious diseases 19900101 |
| In vitro effects of folate inhibitors on Toxoplasma gondii. | Antimicrobial agents and chemotherapy 19891001 |
| Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule. | Cancer research 19880901 |
| Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate. | Antimicrobial agents and chemotherapy 19880401 |
| Activity of lipid-soluble inhibitors of dihydrofolate reductase against Pneumocystis carinii in culture and in a rat model of infection. | Antimicrobial agents and chemotherapy 19870901 |
| Potent effect of trimetrexate, a lipid-soluble antifolate, on Toxoplasma gondii. | The Journal of infectious diseases 19870501 |
| Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent. | The Journal of experimental medicine 19870301 |
| Synergistic activity of rabbit granulocyte peptides against Candida albicans. | Infection and immunity 19860601 |